Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells

Ananya Roy, Antoine Coum, Voichita D. Marinescu, Jelena Põlajeva, Anja Smits, Sven Nelander, Lene Uhrbom, Bengt Westermark, Karin Forsberg‐Nilsson, Fredrik Pontén,

Oncotarget · 2015 · 39 citations · 22 references

DOIFull text

Open access

Concepts

Abstract

// Ananya Roy 1,* , Antoine Coum 2,* , Voichita D. Marinescu 3 , Jelena Põlajeva 4 , Anja Smits 5,6 , Sven Nelander 3 , Lene Uhrbom 1 , Bengt Westermark 1 , Karin Forsberg-Nilsson 3 , Fredrik Pontén 3 and Elena Tchougounova 1 1 Uppsala University, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala, Sweden 2 Nanoscience Centre, Department of Engineering, Cambridge University, Cambridge, UK 3 Uppsala University, Department of Immunology, Genetics and Pathology, and Science for Life Laboratory, Rudbeck Laboratory, Uppsala, Sweden 4 Cancer Research Technology, LBIC, London, UK 5 Uppsala University, Department of Neuroscience, Neurology, Uppsala, Sweden 6 Present address: Danish Epilepsy Center, Dianalund, Denmark * These authors have contributed equally to this work Correspondence to: Elena Tchougounova, email: // Keywords : mast cell, glioma, PAI-1, SERPINE1, LRP1 Received : April 28, 2015 Accepted : June 12, 2015 Published : June 25, 2015 Abstract Glioblastoma (GBM) is a high-grade glioma with a complex microenvironment, including various inflammatory cells and mast cells (MCs) as one of them. Previously we had identified glioma grade-dependent MC recruitment. In the present study we investigated the role of plasminogen activator inhibitor 1 (PAI-1) in MC recruitment. PAI-1, a primary regulator in the fibrinolytic cascade is capable of forming a complex with fibrinolytic system proteins together with low-density lipoprotein receptor-related protein 1 (LRP1). We found that neutralizing PAI-1 attenuated infiltration of MCs. To address the potential implication of LRP1 in this process, we used a LRP1 antagonist, receptor-associated protein (RAP), and demonstrated the attenuation of MC migration. Moreover, a positive correlation between the number of MCs and the level of PAI-1 in a large cohort of human glioma samples was observed. Our study demonstrated the expression of LRP1 in human MC line LAD2 and in MCs in human high-grade glioma. The activation of potential PAI-1/LRP1 axis with purified PAI-1 promoted increased phosphorylation of STAT3 and subsequently exocytosis in MCs. These findings indicate the influence of the PAI-1/LRP1 axis on the recruitment of MCs in glioma. The connection between high-grade glioma and MC infiltration could contribute to patient tailored therapy and improve patient stratification in future therapeutic trials.

References

22